MedPath

A Pilot Study of Metabolic Effects of Omentectomy

Phase 2
Terminated
Conditions
Confirmed Type 2 Diabetes Treated With Oral Agents and/or Only Diet Therapy
Patients Who Consented to Undergo Laparoscopic Gastric Banding Surgery for Weight Loss and Consent to Participate in This studyBMI ≥35 kg/m2
Age 18-64 Years
Interventions
Procedure: Omentectomy
Other: No intervention
Registration Number
NCT00565799
Lead Sponsor
NYU Langone Health
Brief Summary

PROTOCOL SUMMARY

Type of Study: Pilot, randomized and single center trial Test Procedure: Omentectomy Aim 1. Determine the effect of omentectomy on 1) insulin sensitivity, 2) beta cell function and 3) plasma markers of inflammation We hypothesize that removal of omental fat increases insulin sensitivity and pancreatic sensitivity to glucose, and decreases systemic inflammation.

Aim 2. Identify genes and proteins in adipocytes from obese patients that affect clinical presentation versus those that are affected by obesity for future study.

We hypothesize that the genetic samples will help us to identify genes and proteins in adipocytes from obese patients that affect clinical presentation versus those that are affected by obesity and help us to design future obesity genetic studies.

Total Enrollment Number: 30 patients who are scheduled to undergo bariatric surgery for weight loss at New York University Medical Center will be invited to participate in this study. Subjects will be randomly assigned, by using a computer-generated randomization scheme, in a single-blind fashion to either the omentectomy (n=15) or control group (n=15).

Detailed Description

Inclusion Criteria:

* Patients who consented to undergo LAGB for weight loss and consent to participate in this study

* BMI ≥35 kg/m2

* Confirmed T2DM treated with oral agents and/or only diet therapy

* Age 18-64 years

Exclusion Criteria:

* Insulin therapy

* Weight change (\>2% body weight) within 4 weeks before surgery

* Patients with T2DM for more than 10 years

Research Design- Pilot Study Event Week (approximate) Medical Screening (in conjunction with routine pre-op visit) -4 OGTT \& randomization -2 Preliminary genetic testing for the future study (blood sample) -2 Surgery with or without omentectomy 0 Preliminary genetic testing for the future study (fat sample) 0 Weight stabilization visit (in conjunction with routine post-op visit) 2 Weight stabilization visit (in conjunction with routine post-op visit) 4 OGTT 6

STUDY PLAN

Study has approved by IRB, NYU School of Medicine Committee, GCRC, and Bellevue Hospital.

Study initiation date: November 01, 2007

Enrollment period: Nov. 2007 to Nov. 2008

Study period: Nov. 2007 to Jan 2008

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • Patients who consented to undergo LAGB for weight loss and consent to participate in this study
  • BMI ≥35 kg/m2
  • Confirmed T2DM treated with oral agents and/or only diet therapy
  • Age 18-64 years
Exclusion Criteria
  • Insulin therapy
  • Weight change (>2% body weight) within 4 weeks before surgery
  • Patients with T2DM for more than 10 years

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1. OmentectomyOmentectomyLAGB \& Omentectomy
2 No OmentectomyNo interventionLAGB Only
Primary Outcome Measures
NameTimeMethod
1) insulin sensitivity, 2) beta cell function and 3) plasma markers of inflammation6 week post op
Secondary Outcome Measures
NameTimeMethod
Identify genes and proteins in adipocytes from obese patients that affect clinical presentation versus those that are affected by obesity for future study.6 week post op

Trial Locations

Locations (1)

NYU School of Medicine

🇺🇸

NY, New York, United States

© Copyright 2025. All Rights Reserved by MedPath